301 related articles for article (PubMed ID: 31298381)
1. TATDN1 promotes the development and progression of breast cancer by targeting microRNA-140-3p.
Yu XY; Tian JR; Yang D; Tan HR
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5293-5300. PubMed ID: 31298381
[TBL] [Abstract][Full Text] [Related]
2. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-1236-3p inhibits proliferation and invasion of breast cancer cells by targeting ZEB1.
Liang TC; Fu WG; Zhong YS
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9988-9995. PubMed ID: 31799668
[TBL] [Abstract][Full Text] [Related]
4. Circular RNA-100219 promotes breast cancer progression by binding to microRNA-485-3p.
Yao Y; Fang ZZXHSLCNH
J BUON; 2019; 24(2):501-508. PubMed ID: 31127997
[TBL] [Abstract][Full Text] [Related]
5. LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p.
Li J; Wang AS; Wang S; Wang CY; Xue S; Guan H; Li WY; Ma TT; Shan YX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1022-1029. PubMed ID: 30779068
[TBL] [Abstract][Full Text] [Related]
6. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186.
Luo X; Song Y; Tang L; Sun DH; Ji DG
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7788-7797. PubMed ID: 30536320
[TBL] [Abstract][Full Text] [Related]
7. LncRNA RUSC1-AS1 promotes the proliferation of breast cancer cells by epigenetic silence of KLF2 and CDKN1A.
Hu CC; Liang YW; Hu JL; Liu LF; Liang JW; Wang R
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6602-6611. PubMed ID: 31378902
[TBL] [Abstract][Full Text] [Related]
8. LncRNA LOXL1-AS1 inhibited cell proliferation, migration and invasion as well as induced apoptosis in breast cancer via regulating miR-143-3p.
Li GH; Yu JH; Yang B; Gong FC; Zhang KW
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10400-10409. PubMed ID: 31841194
[TBL] [Abstract][Full Text] [Related]
9. LncSNHG14 promotes ovarian cancer by targeting microRNA-125a-5p.
Zhao YL; Huang YM
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3235-3242. PubMed ID: 31081075
[TBL] [Abstract][Full Text] [Related]
10. LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis.
Liu X; Yao W; Xiong H; Li Q; Li Y
Cancer Biomark; 2020; 29(2):277-290. PubMed ID: 32675392
[TBL] [Abstract][Full Text] [Related]
11. LncRNA HOTTIP promotes proliferation and cell cycle progression of acute myeloid leukemia cells.
Zhuang MF; Li LJ; Ma JB
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2908-2915. PubMed ID: 31002141
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells.
Wang C; Xie XX; Li WJ; Jiang DQ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10410-10421. PubMed ID: 31841195
[TBL] [Abstract][Full Text] [Related]
13. LncRNA TATDN1 induces the progression of hepatocellular carcinoma via targeting miRNA-6089.
Shen C; Xu Y; Lu TF; Zhang JJ; Qian YB; Xu N
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6459-6466. PubMed ID: 31378885
[TBL] [Abstract][Full Text] [Related]
14. LncRNA AK024094 aggravates the progression of breast cancer through regulating miRNA-181a.
Zheng TZ; Li YT; Li WJ
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1913-1921. PubMed ID: 32141560
[TBL] [Abstract][Full Text] [Related]
15. Long-chain non-coding RNA GACAT1 promotes development and progression of breast cancer by targeting microRNA-875-3p.
Wang Q; Xue J; Ren Q; Li X; Qiu X
Oncol Lett; 2020 Mar; 19(3):2547-2553. PubMed ID: 32194758
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA SNHG15 accelerates the progression of non-small cell lung cancer by absorbing miR-211-3p.
Ma XR; Xu YL; Qian J; Wang Y
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1536-1544. PubMed ID: 30840276
[TBL] [Abstract][Full Text] [Related]
17. LncRNA LINP1 promotes malignant progression of pancreatic cancer by adsorbing microRNA-491-3p.
Chen AY; Zhang K; Liu GQ
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9315-9324. PubMed ID: 33015772
[TBL] [Abstract][Full Text] [Related]
18. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
19. LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.
Liu SQ; Zhou ZY; Dong X; Guo L; Zhang KJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32538432
[TBL] [Abstract][Full Text] [Related]
20. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2.
Zhou Q; Guo J; Huang W; Yu X; Xu C; Long X
Mol Oncol; 2020 Sep; 14(9):2231-2250. PubMed ID: 32335998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
